retatrutide weight loss clinical trials retatrutide Retatrutide, Eli Lilly's next generation of injections, showed dramatic results in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Retatrutide Dosing Explained: What You

It is therefore not available as a licensed medicine in the United Kingdom

What are the ethical considerations in prescribing GLP-1 agonists to women of childbearing potential, given the risks to fetal development and the necessity of contraception

Alcohol: The company's provider guides advise limiting or avoiding alcohol during treatment, especially during dose adjustments, as it may worsen nausea, low blood sugar, or dehydration

Weight loss injections like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have raised important questions about reproductive health

Dizziness and headaches: These symptoms occurred in some trial participants, typically during the bodys adjustment to the medication

For context, tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist, and semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist